X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Beyond 2005 - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Aug 21, 2003

    Pharma: Beyond 2005

    The pharma stocks are off late having a dream run on the bourses. Most of the stocks have breached their 52-week high levels, while others are on the verge of crossing the same. The rally has been across the board and even the mid-cap stocks have benefited.

    Although the upswing is not justifiable for all stocks, there is no denying the fact that the pharma industry as a whole has tremendous growth potential. The growth potential is seen mainly in the exports market combined with outsourcing opportunities from foreign counterparts. However, the hype surrounding these opportunities has resulted in ignoring the very crucial domestic pharma market.

    The domestic market has been showing low growth rates for quite some time now. This has been mainly due to the fact that the prices of drugs are regulated thereby restricting the realizations growth. But does that mean that there is no potential for growth in the domestic market. Take a look at the following chart.

    As can be seen from the above chart, the expenditure on healthcare as a percentage of GDP is only 4.9% as against 5.3% in China, 7.8% in Japan and as high as 13% in the US. So does this mean that the Indians do not fall sick or that they are very close-fisted when it comes to spending on health. So, what are the reasons for such poor spending?

    A close look at the above graph indicates that the government's contribution to the total health expenditure is the lowest in India (17.8%). In comparison, China (36.6%), Brazil (40.8%) and USA (44.3%) have a major portion of their health spending financed by the government, which is yet to break ground in India in a big way. This is primarily on account of lack of adequate social security cover to Indian citizens as compared to the other countries. Although there have been some efforts on this front by the government (like the health insurance cover provided to farmers in South India), it is not enough. The public health facilities that were initiated with the purpose of providing cost effective medication to citizens have met with little success. Hence, Indians will have to continue financing a major portion of the health expenditure through their pockets. But will they be able to do so? This is where health insurance comes in.

    Health insurance has not been very popular in India. Rigid price regulations on drug prices and the availability of low cost generics ensured that the medical cost were not very high. Even those who did take a medical cover did so solely for the purpose of claiming tax deductions. Thus, there was very little awareness among the Indian masses regarding health insurance. This coupled with lack of innovation in insurance cover for medical purposes have resulted in very few people opting for the same. Further, the premium charged also ensured that that policies remain beyond the bounds of a majority of the Indian population.

    However, post 2005, with the introduction of product patents, the prices of medicines in India could increase many folds. Thus, people will find it increasingly difficult to meet their medical expenses and will consider having an insurance cover over their health expenses. Further, with the opening up of the insurance sector, many private players have also entered the market with attractive mediclaim policies. All these factors could translate into higher subscriptions to these policies and consequently a drop in the premium charges thereby making it even more affordable.

    Consequently, post 2005, although drug prices could rise, the health insurance will provide a cushion. There will thus be an increase in the domestic spending on medical expenditure resulting in a sharp rise in the revenues for the companies competing in the domestic markets. Thus, going international need not be the only strategy for survival for a domestic pharma company. The growth opportunities in the domestic market over the longer term remains promising.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: Beyond 2005". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 18, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS